PharmGen Science, Inc. (KRX: 004720)
South Korea
· Delayed Price · Currency is KRW
4,215.00
-130.00 (-2.99%)
Dec 20, 2024, 3:30 PM KST
PharmGen Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | -1,235 | 5,727 | 70,060 | 32,466 | 9,222 | 301.98 | Upgrade
|
Depreciation & Amortization | 4,639 | 4,247 | 3,371 | 3,142 | 2,963 | 2,322 | Upgrade
|
Loss (Gain) From Sale of Assets | -19.98 | -46.35 | -1.94 | 11.49 | 29.13 | -121.4 | Upgrade
|
Asset Writedown & Restructuring Costs | - | 228.3 | 133.08 | 799.9 | 53.75 | - | Upgrade
|
Loss (Gain) From Sale of Investments | 1,458 | -51.6 | -9.77 | -1.11 | 1,085 | -43.58 | Upgrade
|
Loss (Gain) on Equity Investments | 10,196 | 2,996 | -87,213 | -46,633 | -14,508 | 2.15 | Upgrade
|
Stock-Based Compensation | - | - | - | 4,359 | 1,671 | - | Upgrade
|
Provision & Write-off of Bad Debts | -28.37 | -125.07 | -289.72 | 5.11 | 1,243 | 1,583 | Upgrade
|
Other Operating Activities | 1,519 | -1,003 | 25,467 | 9,532 | 5,866 | -711.68 | Upgrade
|
Change in Accounts Receivable | -8,795 | -7,454 | -7,901 | 1,433 | -3,480 | -1,579 | Upgrade
|
Change in Inventory | -3,870 | 186.91 | -5,675 | 1,195 | -2,639 | -1,795 | Upgrade
|
Change in Accounts Payable | -1,314 | -70.57 | 433.75 | 24.39 | 398.27 | 2,232 | Upgrade
|
Change in Other Net Operating Assets | 793.28 | 804.17 | 340.48 | 1,450 | 771.63 | 333.96 | Upgrade
|
Operating Cash Flow | 3,343 | 5,439 | -1,286 | 7,784 | 2,676 | 2,523 | Upgrade
|
Operating Cash Flow Growth | -20.27% | - | - | 190.93% | 6.03% | -40.14% | Upgrade
|
Capital Expenditures | -868.86 | -2,266 | -9,922 | -30,750 | -4,339 | -6,160 | Upgrade
|
Sale of Property, Plant & Equipment | 63.28 | 80 | 190.25 | 46.58 | 5.3 | 2.43 | Upgrade
|
Cash Acquisitions | - | - | - | - | - | -0.18 | Upgrade
|
Sale (Purchase) of Intangibles | -1,882 | -985.79 | -2,034 | -3,260 | -582.75 | -622.78 | Upgrade
|
Investment in Securities | -0 | 6,490 | -3,498 | 1,501 | -550 | -4,283 | Upgrade
|
Other Investing Activities | 598.03 | -58.67 | -20.38 | 2,077 | -2,254 | 109.03 | Upgrade
|
Investing Cash Flow | -2,089 | 3,260 | -15,284 | -30,385 | -7,721 | -10,955 | Upgrade
|
Short-Term Debt Issued | - | - | 389.68 | 1,169 | - | - | Upgrade
|
Long-Term Debt Issued | - | 11,200 | 33,300 | 49,779 | 20,500 | 14,300 | Upgrade
|
Total Debt Issued | - | 11,200 | 33,690 | 50,948 | 20,500 | 14,300 | Upgrade
|
Short-Term Debt Repaid | - | - | -2,338 | - | - | - | Upgrade
|
Long-Term Debt Repaid | - | -2,633 | -30,880 | -20,428 | -983.48 | -16,699 | Upgrade
|
Total Debt Repaid | -2,864 | -2,633 | -33,218 | -20,428 | -983.48 | -16,699 | Upgrade
|
Net Debt Issued (Repaid) | -2,864 | 8,567 | 471.8 | 30,521 | 19,517 | -2,399 | Upgrade
|
Other Financing Activities | 258.71 | 284.59 | 1,797 | -180.05 | 51.18 | -187.5 | Upgrade
|
Financing Cash Flow | -2,605 | 8,852 | 2,269 | 30,340 | 19,568 | -2,586 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 0 | 0 | - | - | 0 | 0 | Upgrade
|
Net Cash Flow | -1,351 | 17,551 | -14,302 | 7,739 | 14,523 | -11,018 | Upgrade
|
Free Cash Flow | 2,474 | 3,173 | -11,208 | -22,966 | -1,664 | -3,637 | Upgrade
|
Free Cash Flow Margin | 1.43% | 1.90% | -7.43% | -20.90% | -1.72% | -3.82% | Upgrade
|
Free Cash Flow Per Share | 136.63 | 152.58 | -519.12 | -1234.84 | -110.74 | -315.08 | Upgrade
|
Cash Interest Paid | 1,617 | 2,112 | 1,718 | 1,112 | 297.81 | 608.71 | Upgrade
|
Cash Income Tax Paid | 1,936 | 2,124 | 52.99 | 866.9 | 209.36 | 3,154 | Upgrade
|
Levered Free Cash Flow | -3,692 | -6,644 | -8,116 | -23,020 | -6,110 | -6,168 | Upgrade
|
Unlevered Free Cash Flow | -1,027 | -3,979 | -5,922 | -21,944 | -5,929 | -5,245 | Upgrade
|
Change in Net Working Capital | 10,916 | 10,678 | 1,970 | -7,651 | 4,450 | 1,533 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.